Genmab announced termination of clinical development for acasunlimab, a bispecific antibody that had been developed with BioNTech before the partner withdrew last year. Genmab said the decision follows reassessment of the asset’s clinical profile and strategic priorities, effectively ending work on the molecule that targeted a dual immune axis in oncology. Acasunlimab’s discontinuation reflects the broader rebalancing of bispecific and oncology pipelines across biotech as companies prioritize resources for assets with clearer differentiation or stronger clinical signals. Genmab will reallocate resources to other pipeline programs and assess potential options for any related intellectual property. The move underscores both the dependency of smaller programs on partnership economics and the high attrition rate for complex multispecific modalities in late‑stage development.